Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 63.494
Filtrar
3.
J Urol ; 202(3): 475-483, 2019 09.
Artigo em Inglês | MEDLINE | ID: mdl-31412438

RESUMO

PURPOSE: Renal colic is common and CT (computerized tomography) is frequently utilized when the diagnosis of kidney stone is suspected. CT is accurate, but exposes patients to ionizing radiation and has not been shown to alter either interventional approaches or hospital admission rates. This multi-organizational transdisciplinary collaboration sought evidence-based, multispecialty consensus on optimal imaging across different clinical scenarios in patients with suspected renal colic in the acute setting. MATERIALS AND METHODS: In conjunction with the ACEP (American College of Emergency Physicians®) E-QUAL (Emergency Quality Network) we formed a nine-member panel with three physician representatives each from the ACEP, the ACR® (American College of Radiology) and the AUA (American Urological Association). A systematic literature review was used as the basis for a 3-step modified Delphi process to seek consensus on optimal imaging in 29 specific clinical scenarios. RESULTS: From an initial search yielding 6,337 records there were 232 relevant articles of acceptable evidence quality to guide the literature summary. At the completion of the Delphi process consensus, agreement was rated as perfect in 15 (52%), excellent in 8 (28%), good in 3 (10%) and moderate in 3 (10%) of the 29 scenarios. There were no scenarios where at least moderate consensus was not reached. CT was recommended in 7 scenarios (24%) with ultrasound in 9 (31%) and no further imaging needed in 13 (45%). CONCLUSIONS: Evidence and multispecialty consensus support ultrasound or no further imaging in specific clinical scenarios, with reduced-radiation dose CT to be employed when CT is needed in patients with suspected renal colic.


Assuntos
Consenso , Cólica Renal/diagnóstico por imagem , Sociedades Médicas/normas , Tomografia Computadorizada por Raios X/normas , Ultrassonografia/normas , Técnica Delfos , Medicina de Emergência/normas , Humanos , Comunicação Interdisciplinar , Radiologia/normas , Tomografia Computadorizada por Raios X/efeitos adversos , Estados Unidos , Urologia/normas
4.
Arq Gastroenterol ; 56(2): 213-231, 2019 Aug 13.
Artigo em Inglês | MEDLINE | ID: mdl-31460590

RESUMO

Liver and biliary tract diseases are common causes of morbidity and mortality worldwide. Invasive procedures are usually performed in those patients with hepatobiliary diseases for both diagnostic and therapeutic purposes. Defining proper indications and restraints of commonly used techniques is crucial for proper patient selection, maximizing positive results and limiting complications. In 2018, the Brazilian Society of Hepato-logy (SBH) in cooperation with the Brazilian Society of Interventional Radiology and Endovascular surgery (SOBRICE) and the Brazilian Society of Digestive Endoscopy (SOBED) sponsored a joint single-topic meeting on invasive procedures in patients with hepatobiliary diseases. This paper summarizes the proceedings of the aforementioned meeting. It is intended to guide clinicians, gastroenterologists, hepatologists, radiologists, and endoscopists for the proper use of invasive procedures for management of patients with hepatobiliary diseases.


Assuntos
Doenças Biliares/cirurgia , Hepatopatias/cirurgia , Brasil , Gerenciamento Clínico , Guias como Assunto , Humanos , Sociedades Médicas
5.
Arq Gastroenterol ; 56(2): 232-241, 2019 Aug 13.
Artigo em Inglês | MEDLINE | ID: mdl-31460591

RESUMO

New data concerning the management of autoimmune liver diseases have emerged since the last single-topic meeting sponsored by the Brazilian Society of Hepatology to draw recommendations about the diagnosis and treatment of autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), overlap syndromes of AIH, PBC and PSC and specific complications and topics concerning AIH and cholestatic liver diseases. This manuscript updates those previous recommendations according to the best evidence available in the literature up to now. The same panel of experts that took part in the first consensus document reviewed all recommendations, which were subsequently scrutinized by all members of the Brazilian Society of Hepatology using a web-based approach. The new recommendations are presented herein.


Assuntos
Doenças Autoimunes/diagnóstico , Doenças Autoimunes/terapia , Hepatopatias/diagnóstico , Hepatopatias/terapia , Colangite Esclerosante/diagnóstico , Colangite Esclerosante/terapia , Gerenciamento Clínico , Hepatite Autoimune/diagnóstico , Hepatite Autoimune/terapia , Humanos , Cirrose Hepática Biliar/diagnóstico , Cirrose Hepática Biliar/terapia , Sociedades Médicas
8.
Gastroenterology ; 157(2): 320-348, 2019 08.
Artigo em Inglês | MEDLINE | ID: mdl-31320109

RESUMO

BACKGROUND & AIMS: We aim to provide guidance for medical treatment of luminal Crohn's disease in children. METHODS: We performed a systematic search of publication databases to identify studies of medical management of pediatric Crohn's disease. Quality of evidence and strength of recommendations were rated according to the GRADE (Grading of Recommendation Assessment, Development, and Evaluation) approach. We developed statements through an iterative online platform and then finalized and voted on them. RESULTS: The consensus includes 25 statements focused on medical treatment options. Consensus was not reached, and no recommendations were made, for 14 additional statements, largely due to lack of evidence. The group suggested corticosteroid therapies (including budesonide for mild to moderate disease). The group suggested exclusive enteral nutrition for induction therapy and biologic tumor necrosis factor antagonists for induction and maintenance therapy at diagnosis or at early stages of severe disease, and for patients failed by steroid and immunosuppressant induction therapies. The group recommended against the use of oral 5-aminosalicylate for induction or maintenance therapy in patients with moderate disease, and recommended against thiopurines for induction therapy, corticosteroids for maintenance therapy, and cannabis in any role. The group was unable to clearly define the role of concomitant immunosuppressants during initiation therapy with a biologic agent, although thiopurine combinations are not recommended for male patients. No consensus was reached on the role of aminosalicylates in treatment of patients with mild disease, antibiotics or vedolizumab for induction or maintenance therapy, or methotrexate for induction therapy. Patients in clinical remission who are receiving immunomodulators should be assessed for mucosal healing within 1 year of treatment initiation. CONCLUSIONS: Evidence-based medical treatment of Crohn's disease in children is recommended, with thorough ongoing assessments to define treatment success.


Assuntos
Doença de Crohn/tratamento farmacológico , Medicina Baseada em Evidências/normas , Gastroenterologia/normas , Fármacos Gastrointestinais/uso terapêutico , Sociedades Médicas/normas , Canadá , Criança , Medicina Baseada em Evidências/métodos , Gastroenterologia/métodos , Humanos , Resultado do Tratamento
9.
Ann Hematol ; 98(9): 2213-2220, 2019 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-31327025

RESUMO

Alemtuzumab is the treatment choice for patients with T-prolymphocytic leukemia (T-PLL). However, patients with T-PLL have a poor prognosis, and the option of allogeneic hematopoietic cell transplantation (HCT) remains controversial in these patients. This study aimed to analyze the outcomes of allogeneic HCT among patients with T-PLL to identify the potential clinical efficacy of allogeneic HCT. We retrospectively analyzed data from 20 patients with T-PLL, including five patients with complex chromosomal abnormalities at diagnosis who received an allogeneic HCT between 2000 and 2016. The median follow-up of survivors was 51 months in allogeneic HCT from human leukemia antigen (HLA)-matched donors. All five patients with complex chromosomal abnormalities died after allogeneic HCT. Our data suggest that allogeneic HCT from an HLA-matched donor can be considered for patients with T-PLL without complex chromosomal abnormalities. New treatment strategies of allogeneic HCT are required to improve the safety and efficacy of allografting in patients with T-PLL and complex chromosomal abnormalities. Potential approaches that identify patients with T-PLL and complex chromosomal abnormalities for allogeneic HCT with better disease control may allow identification of individuals who are suitable for allogeneic HCT.


Assuntos
Alemtuzumab/administração & dosagem , Aberrações Cromossômicas , Transplante de Células-Tronco Hematopoéticas , Leucemia Prolinfocítica de Células T , Adulto , Idoso , Aloenxertos , Feminino , Seguimentos , Humanos , Japão/epidemiologia , Leucemia Prolinfocítica de Células T/genética , Leucemia Prolinfocítica de Células T/mortalidade , Leucemia Prolinfocítica de Células T/terapia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Sociedades Médicas , Resultado do Tratamento
10.
World J Pediatr Congenit Heart Surg ; 10(4): 492-498, 2019 07.
Artigo em Inglês | MEDLINE | ID: mdl-31307301

RESUMO

The World Database for Pediatric and Congenital Heart Surgery was created to provide a resource for centers to be able to perform complex outcomes analyses of children undergoing repair of a congenital heart defect. In just under two years, the World Society for Pediatric and Congenital Heart Surgery (WSPCHS) has amassed over 13,000 procedures from 55 centers into the database. This Proceedings of the 3rd World Database Symposium held at the 6th Scientific Meeting of the WSPCHS summarizes the presentations of international experts in the fields of outcomes analysis and care of children with congenital heart surgery.


Assuntos
Procedimentos Cirúrgicos Cardíacos , Congressos como Assunto , Cardiopatias Congênitas/cirurgia , Sociedades Médicas , Cirurgia Torácica , Criança , Bases de Dados Factuais , Humanos
11.
World J Pediatr Congenit Heart Surg ; 10(4): 454-463, 2019 07.
Artigo em Inglês | MEDLINE | ID: mdl-31307308

RESUMO

BACKGROUND: The completeness and accuracy of data contained within clinical databases and registries is critical to the reliability of reports emanating from these platforms. Therefore, vigorous data verification processes are a core competency of any mature database or registry. The Society of Thoracic Surgeons Congenital Heart Surgery Database (STS CHSD) has conducted audits of participant data for just over ten years. This report documents the validity of data elements within the STS CHSD. METHODS: We review the various elements of a robust audit process, detail the STS CHSD audit methodology, and report completeness and agreement rates for all adjudicated fields in the most recently completed audit. RESULTS: The rate of completeness for general data elements was 97.6% and the rate of agreement was 97.4%. The rate of completeness for variables in the mortality review was 100% and the rate of agreement was 99.3%. CONCLUSIONS: The STS CHSD audit is a highly structured and reproducible process. The most recently completed audit documents a very high level of completeness and accuracy of data variables, particularly those most germane to outcomes measurement.


Assuntos
Procedimentos Cirúrgicos Cardíacos/estatística & dados numéricos , Auditoria Clínica/estatística & dados numéricos , Cardiopatias Congênitas/cirurgia , Avaliação de Resultados (Cuidados de Saúde)/estatística & dados numéricos , Sistema de Registros , Sociedades Médicas , Cirurgia Torácica/estatística & dados numéricos , Bases de Dados Factuais , Humanos , Cirurgiões/estatística & dados numéricos
12.
Arch Endocrinol Metab ; 63(3): 190-198, 2019 Jul 18.
Artigo em Inglês | MEDLINE | ID: mdl-31340240

RESUMO

OBJECTIVE: To summarize current evidence regarding testosterone treatment for women with low sexual desire. MATERIALS AND METHODS: The Female Endocrinology and Andrology Department of the Brazilian Society of Endocrinology and Metabolism invited nine experts to review the physiology of testosterone secretion and the use, misuse, and side effects of exogenous testosterone therapy in women, based on the available literature and guidelines and statements from international societies. RESULTS: Low sexual desire is a common complaint in clinical practice, especially in postmenopausal women, and may negatively interfere with quality of life. Testosterone seems to exert a positive effect on sexual desire in women with sexual dysfunction, despite a small magnitude of effect, a lack of long-term safety data, and insufficient evidence to make a broad recommendation for testosterone therapy. Furthermore, there are currently no testosterone formulations approved for women by the relevant regulatory agencies in the United States, Brazil, and most other countries, and testosterone formulations approved for men are not recommended for use by women. CONCLUSION: Therefore, testosterone therapy might be considered if other strategies fail, but the risks and benefits must be discussed with the patient before prescription. Arch Endocrinol Metab. 2019;63(3):190-8.


Assuntos
Androgênios/uso terapêutico , Libido/efeitos dos fármacos , Disfunções Sexuais Fisiológicas/tratamento farmacológico , Testosterona/uso terapêutico , Adolescente , Adulto , Idoso , Androgênios/efeitos adversos , Androgênios/sangue , Feminino , Humanos , Pessoa de Meia-Idade , Guias de Prática Clínica como Assunto , Sociedades Médicas , Testosterona/efeitos adversos , Testosterona/sangue , Adulto Jovem
13.
Can Assoc Radiol J ; 70(3): 226-232, 2019 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-31255393

RESUMO

In 2017, the Canadian Association of Radiologists issued a clinical practice guideline (CPG) regarding the use of gadolinium-based contrast agents (GBCAs) in patients with acute kidney injury (AKI), chronic kidney disease (CKD), or on dialysis due to mounting evidence indicating that nephrogenic systemic fibrosis (NSF) occurs with extreme rarity or not at all when using Group II GBCAs or the Group III GBCA gadoxetic acid (compared to first generation Group I linear GBCAs). One of the goals of the work group was to re-evaluate the CPG after 24 months to determine the effect of more liberal use of GBCA on reported cases of NSF in patients with AKI, CKD Stage 4 or 5 (estimated glomerular filtration rate [eGFR] < 30 mL/min/1.73 m2), or those that are dialysis-dependent. A comprehensive review of the literature was conducted by a subcommittee of the initial CPG panel between the dates of January 1, 2017-December 31, 2018 to identify new unconfounded cases of NSF linked to Group II or Group III GBCAs and an updated CPG developed. To our knowledge, when using a Group II or Group III GBCA between 2017-2018, only a single unconfounded case report of a fibrosing dermopathy has been reported in a patient who received gadobenate dimeglumine with Stage 2 CKD. No other unconfounded cases of NSF have been reported with Group II or III agents in during this timeframe. The subcommittee concluded that the main recommendations from the 2017 CPG should remain unaltered, but agreed that screening for renal disease in the outpatient setting is no longer justifiable, cost-effective or recommended. Patients on hemodialysis (HD) should, however, be identified prior to GBCA administration to arrange timely HD to optimize gadolinium clearance, although there remains no evidence that HD reduces the risk of NSF. When administering Group II or III GBCAs to patients with AKI, on dialysis or with severe CKD, informed consent relating to NSF is also no longer explicitly recommended.


Assuntos
Meios de Contraste , Gadolínio , Aumento da Imagem/métodos , Nefropatias/diagnóstico por imagem , Imagem por Ressonância Magnética , Canadá , Humanos , Rim/diagnóstico por imagem , Radiologistas , Sociedades Médicas
15.
Am Surg ; 85(6): 631-637, 2019 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-31267905

RESUMO

The field of vascularized composite allotransplantation (VCA) has moved from a highly experimental procedure to, at least for some patients, one of the best treatment alternatives for catastrophic tissue loss or dysfunction. Although the worldwide experience is still limited, progress has been made in translation to the clinic, and hand transplantation was recently designated standard of care and is now covered in full by the British Health System. This progress is tempered by the long-term challenges of systemic immunosuppression, and the rapidly evolving indications for VCA such as urogenital transplantation. This update will cover the state of and recent changes in the field, and an update of the Louisville VCA program as our initial recipient, the first person to receive a hand transplant in the United States celebrates the 20th anniversary of his transplant. The achievements and complications encountered over the last two decades will be reviewed. In addition, potential directions for research and collaboration as well as practical issues of how third party payers and funding are affecting growth of the field are presented.


Assuntos
Imunossupressores/administração & dosagem , Procedimentos Cirúrgicos Reconstrutivos/métodos , Alotransplante de Tecidos Compostos Vascularizados/métodos , Feminino , Rejeição de Enxerto , Sobrevivência de Enxerto , Humanos , Masculino , Cuidados Pós-Operatórios/métodos , Complicações Pós-Operatórias/epidemiologia , Complicações Pós-Operatórias/fisiopatologia , Prognóstico , Sociedades Médicas , Imunologia de Transplantes/fisiologia , Alotransplante de Tecidos Compostos Vascularizados/efeitos adversos
19.
Drugs Today (Barc) ; 55(6): 407-415, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-31250844

RESUMO

The theme for this year's meeting of the American Association of Clinical Oncology (ASCO) was 'Caring for Every Patient, Learning from Every Patient'. The meeting consisted of oral, plenary and educational sessions, as well as poster presentations and discussions about important topics in the field of oncology, such as precision medicine, the latest in cancer research impacting patient care, new treatment options and insights for improving access to care. This 55th ASCO annual meeting was held from May 31 to June 4 in Chicago, Illinois, and was attended by over 40,000 cancer experts from around the world who followed a robust program providing opportunities to teach, engage and, most importantly, bring the oncology field together with the aim of improving care for patients with a cancer diagnosis. This report covers some of the later-stage developments and results presented at the meeting.


Assuntos
Oncologia , Neoplasias , Sociedades Médicas , Chicago , Humanos , Medicina de Precisão
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA